Celiac Disease Market Overview, Key Trends, and Major Player Analysis

The celiac disease market is positioned for significant expansion in the coming years, driven by advances in medical research and a growing awareness of the condition. As new treatments and dietary innovations emerge, the landscape for managing celiac disease is evolving quickly, offering promising opportunities for patients and healthcare providers alike. Let's explore the market's expected growth, key players, trends shaping the industry, and the main segments covered in the current market analysis.

Projected Market Value and Growth of the Celiac Disease Market
The size of the celiac disease market is forecasted to reach $1.27 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.0%. This robust expansion is fueled by factors such as the development of novel drugs, innovations in gluten-free food products, personalized nutrition approaches, early screening initiatives, and advancements in microbiome research. Key trends anticipated over the forecast period include increased adoption of gluten-free diets, growth in packaged gluten-free food offerings, expanding drug-based therapies, heightened disease awareness and diagnosis rates, and a growing focus on microbiome-related treatments.

Download a free sample of the celiac disease market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24497&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Companies Making Strides in the Celiac Disease Market
Several prominent players are active in the celiac disease market, including Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., and Entero Therapeutics Inc.

Notably, in May 2025, Targeted Genomics, a US-based firm specializing in celiac disease genetics and wellness, partnered with OraSure Technologies to provide direct-to-consumer genetic testing for celiac disease. This collaboration leverages OraSure's expertise in celiac diagnostics to enhance Targeted Genomics' mission of delivering genetic risk information directly to health-conscious individuals.

View the full celiac disease market report:
https://www.thebusinessresearchcompany.com/report/celiac-disease-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Trends Influencing Innovation in the Celiac Disease Industry
Leading companies are concentrating efforts on advanced treatment options, such as anti-interleukin-15 (IL-15) antibodies, designed to reduce intestinal damage by inhibiting overactive immune responses. These antibodies target IL-15, a cytokine involved in promoting inflammation and immune activity linked to celiac disease. For example, in May 2025, Israeli pharmaceutical company Teva Pharmaceutical Industries announced that the U.S. Food and Drug Administration granted Fast Track designation to TEV-53408, an investigational anti-IL-15 monoclonal antibody. This treatment is aimed at celiac patients who continue experiencing symptoms despite following a gluten-free diet. TEV-53408 is currently undergoing a Phase 2a clinical trial to evaluate its safety and effectiveness by blocking the IL-15 molecule that triggers immune-mediated intestinal damage.

Detailed Segmentation of the Celiac Disease Market
This market report breaks down the celiac disease industry into several important segments:
1) By Treatment: Larazotide Acetate, Gluten-Free Diet, Other Treatments
2) By Route of Administration: Oral, Parenteral
3) By End Users: Hospitals, Homecare, Other End-Users

Further subcategories include:
- Within Larazotide Acetate: Clinical trial phase products, oral capsule formulations, adult celiac patients, pediatric investigational use, monotherapy and combination therapies
- Within Gluten-Free Diet: Packaged gluten-free foods, gluten-free bakery items, gluten-free snacks, gluten-free nutritional supplements, gluten-free beverages
- Within Other Treatments: Corticosteroids, immunosuppressive drugs, enzyme therapies, monoclonal antibodies, probiotics, and microbiome modulators

These segments provide a comprehensive view of treatment options, administration methods, and end-user groups, reflecting the complexity and diversity of the celiac disease treatment landscape.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.